Americans had a substance use disorder in the past year.
Current systems are failing
The barrier is systems readiness.
Ibogaine is not yet positioned to be evaluated and integrated within U.S. healthcare in ways that meet payer, regulator, and health system requirements.
Received treatment.
Of those who receive treatment actually complete it.
Annual cost burden of opioid use disorder per patient per year.
Reported opioid withdrawal eliminated or drastically reduced in a 2017 Johns Hopkins study.
Remission rate for PTSD, depression, and anxiety in the 2024 MISTIC Stanford study.
SUD treatment status quo
Only 8 out of 100 complete treatment.
Current care pathways are not reaching enough people. IHPI focuses on the system conditions required for responsible evaluation, not on promotional claims.
Systems problem
Proof does not automatically become access.
Signals exist, but institutions still see unresolved risk.
- Cost uncertainty
- Safety standards
- Payer requirements
- Coverage questions
Neutral tools translate uncertainty into decision inputs.
- Policy pathways
- Safety guardrails
- Payer frameworks
- Data and outcomes
Coverage, delivery, and monitoring expectations align.
- Coverage criteria
- Site-of-care assumptions
- Monitoring expectations
- Implementation playbooks
Done correctly